On Tuesday, Torrent Pharmaceuticals announced that they have entered the over-the-counter (OTC) market in India with their brand, Shelcal 500. This calcium supplement brand was previously only available as a prescription medication. With this move, the company aims to provide more accessible and affordable healthcare options to consumers.
The OTC market in India has been growing rapidly, and the COVID-19 pandemic has accelerated the trend as consumers are increasingly turning to self-care and home remedies. By entering this segment, Torrent Pharmaceuticals is looking to tap into this trend and expand its product portfolio in the Indian market.
Shelcal 500 is a calcium supplement brand that contains 500mg of calcium and 250 IU of Vitamin D3. This composition helps the body to absorb calcium effectively, which can result in increased bone density, improved muscle strength, and enhanced immunity. By providing the body with the necessary nutrients to strengthen bones and muscles, the supplement can help maintain overall health and well-being. Vitamin D3 is essential for the absorption of calcium, and together with the calcium in Shelcal 500, it can help optimize the body’s use of these vital nutrients.
The calcium in Shelcal 500 is derived from natural sources, such as oyster shell, which has been found to have good absorption and bioavailability in the body. This means that the calcium is easily absorbed and utilized by the body, making it more effective in promoting bone health and other benefits. By using natural sources of calcium, Shelcal 500 aims to provide a safe and effective solution for those looking to improve their bone density and overall health.
According to a statement by Torrent Pharmaceuticals’ Director, Aman Mehta, the entry of Shelcal into the over-the-counter (OTC) market in India positions the brand to become the largest calcium supplement brand in the country. By making the supplement more accessible to consumers, the company hopes to capitalize on the growing demand for self-care and home remedies, as well as increase its market share in India. With its established reputation as a prescription medication, the OTC launch of Shelcal 500 represents a significant move for the brand and for Torrent Pharmaceuticals.
Studies have shown that a significant proportion of the Indian population is deficient in calcium and vitamin D. Specifically, 40.6% of Indians are found to be calcium-deficient, while 79% are vitamin D-deficient. This deficiency can lead to a range of health problems, including weakened bones, muscle weakness, and an increased risk of chronic diseases. By providing a calcium supplement with added Vitamin D3, Shelcal 500 aims to address these deficiencies and provide an accessible and affordable solution for those seeking to improve their bone health and overall wellbeing.
